Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this trial is to assess the impact of CRMD-001 on markers of contrast-induced acute kidney injury (AKI) in high-risk patients with chronic kidney disease (CKD) undergoing coronary angiography and PCI.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CorMedix
• Treatments: Deferiprone

Criteria

Inclusion Criteria:

1. Age 18 or older

2. eGFR of < 60 ml/min/1.73 m2

3. Presence of at least one additional risk factor:

• Diabetes Mellitus

• Age ≥ 75 years

• Left Ventricular Ejection Fraction ≤ 40%

Exclusion Criteria:

1. End-Stage Renal Disease

2. Recent change in serum creatinine

3. Primary PCI for STEMI

4. Currently receiving mechanical ventilation

5. Severe heart failure of cardiogenic shock

6. Requirement for inotropic support (prior 30 days)

7. Sustained hypertension > or = 200/110

8. Subject not expected to live for 90 days

9. Anticipated use of ioxaglate or iohexol

10. Currently receiving fenoldopam, dopamine, theophylline, aminophylline, mannitol, N-acetyl cysteine or Ascorbic acid

11. Absolute neutrophil count < 1500

12. Hemoglobin < 8 gm/dL